{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/prescribing-information/cinnarizine/","result":{"pageContext":{"chapter":{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine","depth":2,"htmlHeader":"<!-- begin field 157e2ac6-5f03-42f0-b74e-a82c00a3b49a --><h2>Cinnarizine</h2><!-- end field 157e2ac6-5f03-42f0-b74e-a82c00a3b49a -->","summary":"","htmlStringContent":"<!-- begin item d92e1238-d42b-4a6f-b5bc-a82c00a3acef --><!-- end item d92e1238-d42b-4a6f-b5bc-a82c00a3acef -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"70ef743a-3673-5faa-aa17-d84c37b14c3f","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field e9798be4-dec6-4645-a14f-a82c00a3eca7 --><h3>What dosage of cinnarizine should I prescribe?</h3><!-- end field e9798be4-dec6-4645-a14f-a82c00a3eca7 -->","summary":"","htmlStringContent":"<!-- begin item 97163999-f57c-4972-be75-a82c00a3ea00 --><!-- begin field 43aa762a-d9a0-4e0d-a7e0-a82c00a3eca7 --><p>For vestibular symptoms, prescribe oral cinnarizine 30 mg three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]. </p><!-- end field 43aa762a-d9a0-4e0d-a7e0-a82c00a3eca7 --><!-- end item 97163999-f57c-4972-be75-a82c00a3ea00 -->","subChapters":[]},{"id":"7bd8bdda-40db-555a-84dc-057ad1f03cf5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e5bec72d-9ad1-412e-ab65-a82c00a40d44 --><h3>What are the contraindications and cautions when prescribing cinnarizine?</h3><!-- end field e5bec72d-9ad1-412e-ab65-a82c00a40d44 -->","summary":"","htmlStringContent":"<!-- begin item 1e779ec9-e481-4659-bbd2-a82c00a40b77 --><!-- begin field c7edbaf4-5054-4cd4-9ee4-a82c00a40d44 --><ul><li>Do not prescribe cinnarizine if the person:<ul><li>Is hypersensitive to cinnarizine or any of its excipients.</li><li>Has porphyria.</li><li>Has severe liver disease (there is an increased risk of coma).</li></ul></li><li>Prescribe cinnarizine with caution if the person has:<ul><li>Parkinson’s disease – give only if the advantages outweigh the risk of disease exacerbation.</li><li>Hepatic or renal impairment.</li><li>Epilepsy.</li><li>Prostatic hypertrophy.</li><li>Pyloroduodenal obstruction.</li><li>Susceptibility to angle closure glaucoma.</li><li>Urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]</p><!-- end field c7edbaf4-5054-4cd4-9ee4-a82c00a40d44 --><!-- end item 1e779ec9-e481-4659-bbd2-a82c00a40b77 -->","subChapters":[]},{"id":"4345c84a-6526-5024-bfd6-0bedc900c915","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d2925eda-03b5-4f40-aa23-a82c00a42663 --><h3>What are the adverse effects of cinnarizine?</h3><!-- end field d2925eda-03b5-4f40-aa23-a82c00a42663 -->","summary":"","htmlStringContent":"<!-- begin item b179837f-b93c-4f28-ae20-a82c00a42497 --><!-- begin field 9aaf2433-7fac-4217-b199-a82c00a42663 --><ul><li>Adverse effects of cinnarizine are more common in older people and include drowsiness, nausea, dyspepsia, and weight gain.</li><li>Less common adverse effects include:<ul><li>Anaphylaxis, angio-oedema.</li><li>Dyskinesia, extrapyramidal disorder, Parkinsonism, tremor, convulsions.</li><li>Cholestatic jaundice.</li><li>Palpitations.</li><li>Bronchospasm.</li><li>Subacute cutaneous lupus erythematosus, lichen planus, photosensitivity reactions, rashes.</li><li>Angle-closure glaucoma.</li><li>Confusion, depression.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]</p><!-- end field 9aaf2433-7fac-4217-b199-a82c00a42663 --><!-- end item b179837f-b93c-4f28-ae20-a82c00a42497 -->","subChapters":[]},{"id":"46ca6142-9c52-5244-97d3-c7ca555438a7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8c856893-b773-4341-91fc-a82c00a44088 --><h3>What drug interactions occur with cinnarizine?</h3><!-- end field 8c856893-b773-4341-91fc-a82c00a44088 -->","summary":"","htmlStringContent":"<!-- begin item c6dad7ce-267e-42ec-bc3a-a82c00a43ec5 --><!-- begin field 00c49ffc-af33-42b3-bb28-a82c00a44088 --><ul><li>Concurrent use of cinnarizine and alcohol, CNS depressants, or tricyclic antidepressants may result in increased sedative effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>]. Advise that this may influence the ability to perform skilled tasks such as driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>].  </li><li>The use of phenelzine in conjunction with cinnarizine increases the risk of antimuscarinic adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>]. </li><li>Avoid using cinnarizine within 4 days of skin testing as it may influence the results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>]. </li></ul><!-- end field 00c49ffc-af33-42b3-bb28-a82c00a44088 --><!-- end item c6dad7ce-267e-42ec-bc3a-a82c00a43ec5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}